DBV Technologies submits BLA to FDA for Viaskin Peanut Patch in children 4-7
DBV asked for Priority Review of the application, which is backed by data from the Phase 3 VITESSE trial in 654 children with peanut allergy.
SEC filing
Latest
2 stories
Tuesday, September 29
Thursday, July 16
DBV Technologies pushes peanut patch BLA filing to third quarter of 2026
The company cited FDA feedback on data formatting as the reason for the delay, and reported cash of $174.9 million funding operations into third quarter of 2027.
SEC filing